Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa J M
Haemostasis. 1986;16(2):159-64. doi: 10.1159/000215286.
Two hundred and seventy patients over 65 years were included in a placebo-controlled randomized double-blind trial to determine whether a small dose of a low molecular weight (LMW) heparin prevents the occurrence of deep vein leg thrombosis (DVT) diagnosed by 125I fibrinogen scanning. LMW heparin (60 mg daily) significantly reduced the frequency of DVT from 9 to 3 percent (p = 0.03). Adverse drug reactions did not differ significantly between the 2 groups, except for the injection site hematomas that were more frequent in the LMW heparin group. In conclusion, LMW heparin appears of value in preventing the occurrence of DVT in an unselected elderly in-patient population.
270名65岁以上的患者被纳入一项安慰剂对照的随机双盲试验，以确定小剂量低分子量（LMW）肝素是否能预防通过125I纤维蛋白原扫描诊断的下肢深静脉血栓形成（DVT）。LMW肝素（每日60毫克）显著降低了DVT的发生率，从9%降至3%（p = 0.03）。两组间药物不良反应无显著差异，但LMW肝素组注射部位血肿更为常见。总之，LMW肝素似乎对预防未经过挑选的老年住院患者发生DVT有价值。
